Do people who choose their treatment in a large randomised trial with parallel preference groups differ at baseline from those who agree to random treatment allocation? Results from the protect study

被引:1
|
作者
Mills, Nicola [1 ]
Khazragui, Hanan [1 ]
Metcalfe, Chris [1 ]
Lane, Athene [1 ]
Davis, Michael [1 ]
Young, Grace [1 ]
Neal, David [2 ]
Hamdy, Freddie [3 ]
Donovan, Jenny [1 ]
机构
[1] Univ Bristol, Bristol, Avon, England
[2] Univ Cambridge, Cambridge, England
[3] Univ Oxford, Oxford, England
来源
TRIALS | 2015年 / 16卷
关键词
Prostate Cancer; Randomise Trial; External Validity; Treatment Preference; Clinical Measure;
D O I
10.1186/1745-6215-16-S2-P109
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
P109
引用
收藏
页数:1
相关论文
共 21 条
  • [21] Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
    Zeidan, Amer M.
    Cavenagh, James
    Voso, Maria Teresa
    Taussig, David
    Tormo, Mar
    Boss, Isaac
    Copeland, Wilbert B.
    Gray, Vanessa E.
    Previtali, Alessandro
    O'Connor, Tim
    Rose, Shelonitda
    Beach, C. L.
    Silverman, Lewis R.
    BLOOD, 2019, 134